Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Company profile
Ticker
ABT
Exchange
Website
CEO
Robert Ford
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Natural Supplement Association, LLC • Abbott Laboratories Co. Canada • Alere Connected Health LTD • Alere UK Holdings Limited ...
IRS number
360698440
ABT stock data
Analyst ratings and price targets
Latest filings (excl ownership)
SD
Conflict minerals disclosure
31 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
S-3ASR
Automatic shelf registration
3 May 23
8-K
Submission of Matters to a Vote of Security Holders
2 May 23
8-K
Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business
19 Apr 23
PX14A6G
Letter to shareholders
10 Apr 23
PX14A6G
Letter to shareholders
4 Apr 23
ARS
2022 FY
Annual report to shareholders
17 Mar 23
DEFA14A
Additional proxy soliciting materials
17 Mar 23
DEF 14A
Definitive proxy
17 Mar 23
Transcripts
ABT
Earnings call transcript
2023 Q1
19 Apr 23
ABT
Earnings call transcript
2022 Q4
25 Jan 23
ABT
Earnings call transcript
2022 Q3
19 Oct 22
ABT
Earnings call transcript
2022 Q2
20 Jul 22
ABT
Earnings call transcript
2022 Q1
20 Apr 22
ABT
Earnings call transcript
2021 Q4
26 Jan 22
ABT
Earnings call transcript
2021 Q3
20 Oct 21
ABT
Earnings call transcript
2021 Q2
22 Jul 21
ABT
Earnings call transcript
2020 Q4
20 Apr 21
ABT
Earnings call transcript
2020 Q4
27 Jan 21
Latest ownership filings
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.16 bn | 9.16 bn | 9.16 bn | 9.16 bn | 9.16 bn | 9.16 bn |
Cash burn (monthly) | 240.33 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 494.41 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 8.67 bn | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 36.1 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2023
73.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2592 |
Opened positions | 139 |
Closed positions | 239 |
Increased positions | 1009 |
Reduced positions | 1036 |
13F shares | Current |
---|---|
Total value | 128.53 tn |
Total shares | 1.27 bn |
Total puts | 6.17 mm |
Total calls | 7.05 mm |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 155.63 mm | $15.76 tn |
BLK Blackrock | 135.57 mm | $13.73 tn |
Capital Research Global Investors | 76.40 mm | $7.74 tn |
STT State Street | 73.45 mm | $7.44 tn |
Capital International Investors | 56.43 mm | $5.71 tn |
MS Morgan Stanley | 36.67 mm | $3.71 tn |
Geode Capital Management | 31.20 mm | $3.15 tn |
NTRS Northern Trust | 23.92 mm | $2.42 tn |
Massachusetts Financial Services | 21.15 mm | $2.14 tn |
Wellington Management | 20.82 mm | $2.11 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 May 23 | Andrea F Wainer | Common shares without par value | Sell | Dispose S | No | No | 110.5607 | 8,226 | 909.47 k | 70,427 |
2 May 23 | Andrea F Wainer | Common shares without par value | Option exercise | Acquire M | No | No | 47 | 8,226 | 386.62 k | 78,653 |
2 May 23 | Andrea F Wainer | Option Common Shares | Option exercise | Dispose M | No | No | 47 | 8,226 | 386.62 k | 0 |
28 Apr 23 | Alpern Robert J | Common shares without par value | Grant | Acquire A | No | No | 0 | 1,816 | 0.00 | 37,297 |
28 Apr 23 | Claire Babineaux-Fontenot | Common shares without par value | Grant | Acquire A | No | No | 0 | 1,816 | 0.00 | 1,816 |
28 Apr 23 | Blount Sally E. | Common shares without par value | Grant | Acquire A | No | No | 0 | 1,816 | 0.00 | 33,157 |
News
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed'
1 Jun 23
Nvidia Chief Flags Dangers To US Chips Act, Disney, Shell, Gucci Allegedly Used Worthless Carbon Credits, Microsoft's Daring Attempt to Outshine Google In Search Game: Today's Top Stories
24 May 23
Is There Collusion in the Baby-Formula Industry?: FTC Scrutinizes State Contracts Bidding Process
24 May 23
Abbott's Baby Formula Brouhaha: Judge Says No Harm, No Foul in Contamination Controversy
23 May 23
Looking At Abbott Laboratories's Recent Unusual Options Activity
23 May 23
Press releases
European Study Finds the Abbott CardioMEMS Sensor Results in Improved Quality of Life and 44% Reduction in Heart Failure Hospitalizations
24 May 23
Abbott Unveils Late-Breaking Data Showing the World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints
20 May 23
Abbott Receives FDA Approval for TactiFlex™ Ablation Catheter for Treatment of Abnormal Heart Rhythm
19 May 23
Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms
19 May 23
Abbott Receives FDA Clearance for Assert-IQ™ Insertable Cardiac Monitor to Help Doctors Monitor People's Heart Rhythms Long-Term
18 May 23